Who Paid My Doc
Imlygic
Biological Oncology
NDC 55513-078-01
General payments
$116,203
Research payments
$58,694,945
Through program year 2025, $116,203 in general payments and $58,694,945 in research payments were reported against Imlygic (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
14 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $233 | 5 |
| 2025 | Research | $102,416 | 14 |
| 2024 | General | $41 | 3 |
| 2024 | Research | $554,606 | 20 |
| 2023 | General | $181 | 7 |
| 2023 | Research | $2,568,277 | 20 |
| 2022 | General | $11,260 | 47 |
| 2022 | Research | $2,997,843 | 59 |
| 2021 | General | $48,136 | 140 |
| 2021 | Research | $13,423,815 | 205 |
| 2020 | General | $16,690 | 71 |
| 2020 | Research | $15,813,262 | 395 |
| 2019 | General | $39,662 | 248 |
| 2019 | Research | $23,234,726 | 410 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
521 general · 1,123 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.